LFST Form 144: 226,518 Shares Proposed Sale Worth $1.23M

LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025.

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025. The filing states an aggregate market value of $1,225,462.38 and reports 388,936,394 shares outstanding. The securities were acquired in a pre-IPO transaction on 06/10/2021, when 1,299,792 shares were obtained from the issuer; payment is noted as equity interests purchased pre-IPO. No sales by the reporting person in the past three months are disclosed. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Insider plans a routine secondary sale of 226,518 shares; size appears small relative to shares outstanding.

The Form 144 documents a proposed brokered sale of 226,518 common shares valued at $1.23 million on 08/18/2025 via Morgan Stanley. The position originated from a pre-IPO acquisition on 06/10/2021 totaling 1,299,792 shares. With 388,936,394 shares outstanding, the proposed sale represents a small percentage of the float, indicating this is likely a routine disposition rather than a material event for the company. The filing also confirms no related sales in the prior three months and includes the standard attestation regarding undisclosed material adverse information.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 mechanics; documentation shows pre-IPO origin and brokered execution.

The notice provides required Rule 144 details: acquisition date, nature of acquisition (pre-IPO), broker name and address, number of shares offered, and aggregate market value. The signer affirms lack of undisclosed material information and indicates no recent sales by the reporting person. From a governance perspective, the filing appears procedurally complete and compliant with Form 144 presentation requirements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LifeStance Health Group (LFST) report on this Form 144?

The filing reports a proposed sale of 226,518 common shares via Morgan Stanley on 08/18/2025, with an aggregate market value of $1,225,462.38.

When were the shares being sold originally acquired?

The shares were acquired on 06/10/2021 in a pre-IPO transaction from the issuer, totaling 1,299,792 shares acquired.

How many LifeStance shares are outstanding according to the filing?

The filing lists 388,936,394 shares outstanding.

Did the reporting person sell any LFST securities in the past three months?

The filing states: Nothing to Report for securities sold during the past three months by the reporting person.

Which broker is handling the proposed sale?

The broker named is Morgan Stanley & Co. LLC, 1585 Broadway, New York, NY 10036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 08:39 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001649053
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIFESTANCE HEALTH GROUP, INC.
SEC File Number	001-40478
Address of Issuer	4800 N. SCOTTSDALE ROAD SUITE 2500 SCOTTSDALE ARIZONA 85251
Phone	602-7672100
Name of Person for Whose Account the Securities are To Be Sold	Silversmith Capital Partners I-C, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	226518	1225462.38	388936394	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/10/2021	Pre-IPO Transactions	Issuer			1299792	06/10/2021	Equity interests in the Issuer were purchased pre-IPO

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sales by Seller should be aggregated with the sale of common stock by Summit Partners Growth Equity Fund IX-A, L.P., Summit Partners Growth Equity Fund IX-B, L.P., Summit Investors GE IX-VC IV, LLC, Summit Investors GE IX-VC IV (UK), L.P., Summit Partners Entrepreneur Advisors II, L.P., Silversmith Capital Partners I-A, L.P., and Silversmith Capital Partners I-B, L.P. (together with Seller, the "Selling Shareholders"). The Selling Shareholders have filed separate Forms 144 for aggregate sales of 12,000,000 shares of common stock during the past three months.
Date of Notice	08/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeff Crisan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)